开云app官网登录入口网页版-官方正版

#吡咯替尼#

5篇内容 | 1669人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2205441, encodeId=4d9322054414f, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=cbef6022e4c' target=_blank style='color:#2F92EE;'>#曲妥珠单抗#</a> <a href='/topic/show?id=2916e177389' target=_blank style='color:#2F92EE;'>#白蛋白结合型紫杉醇#</a> <a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a>, objectTitle=2024 ESMO BC | 吡咯替尼加曲妥珠单抗和白蛋白结合型紫杉醇三联疗法在HER2阳性乳腺癌新辅助治疗中的iDFS结果, objectType=article, longId=825643, objectId=c6da825643da, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240518/1716042406867_5579292.png, objectUrl=/article/show_article.do?id=c6da825643da, replyNumber=0, likeNumber=84, createdTime=2024-05-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c6da825643da, moduleTitle=2024 ESMO BC | 吡咯替尼加曲妥珠单抗和白蛋白结合型紫杉醇三联疗法在HER2阳性乳腺癌新辅助治疗中的iDFS结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c6da825643da)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183114, encodeId=80302183114be, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=e3818e1893' target=_blank style='color:#2F92EE;'>#HER2#</a> <a href='/topic/show?id=f38743453f7' target=_blank style='color:#2F92EE;'>#多西他赛#</a> <a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a>, objectTitle=Nat. Commun：吡咯替尼联合多西紫杉醇作为HER2阳性转移性乳腺癌的一线治疗：PANDORA II期临床试验, objectType=article, longId=810433, objectId=91df8104338a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016679583_4754896.png, objectUrl=/article/show_article.do?id=91df8104338a, replyNumber=0, likeNumber=105, createdTime=2024-01-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=91df8104338a, moduleTitle=Nat. Commun：吡咯替尼联合多西紫杉醇作为HER2阳性转移性乳腺癌的一线治疗：PANDORA II期临床试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=91df8104338a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2181792, encodeId=0e1f2181e92ca, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a> <a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=Nat. Commun | 吡罗替尼联合多西紫杉醇作为HER2阳性转移性乳腺癌的一线治疗：PANDORA II期试验, objectType=article, longId=808861, objectId=f441808861fc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240110/1704893487429_6145188.png, objectUrl=/article/show_article.do?id=f441808861fc, replyNumber=0, likeNumber=70, createdTime=2024-01-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f441808861fc, moduleTitle=Nat. Commun | 吡罗替尼联合多西紫杉醇作为HER2阳性转移性乳腺癌的一线治疗：PANDORA II期试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f441808861fc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2180529, encodeId=98b02180529ab, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a> <a href='/topic/show?id=63c84e613e8' target=_blank style='color:#2F92EE;'>#局部放疗#</a>, objectTitle=客观缓解率近90%！JAMA子刊：乳腺癌脑转移治疗迎来突破！, objectType=article, longId=808826, objectId=1a868088261f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/conference-with-doctors-in-medical-aprons-PT29AAG.jpg, objectUrl=/article/show_article.do?id=1a868088261f, replyNumber=0, likeNumber=102, createdTime=2024-01-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=1a868088261f, moduleTitle=客观缓解率近90%！JAMA子刊：乳腺癌脑转移治疗迎来突破！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1a868088261f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2172152, encodeId=edbf21e2152fd, content=<a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a>联合<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>和化疗一线治疗<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>晚期<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>具有令人惊喜的疗效结果。, objectTitle=疾病控制率100%！《柳叶刀》子刊：胃癌一线治疗有望迎来重磅疗法！, objectType=article, longId=801776, objectId=c363801e764a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/type2diabetes-s2-stomach-and-pancreas.jpg, objectUrl=/article/show_article.do?id=c363801e764a, replyNumber=0, likeNumber=80, createdTime=2023-11-30, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=c363801e764a, moduleTitle=疾病控制率100%！《柳叶刀》子刊：胃癌一线治疗有望迎来重磅疗法！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c363801e764a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2162587, encodeId=817a216258e36, content=<a href='/topic/show?id=2cb21063650c' target=_blank style='color:#2F92EE;'>#达尔西利#</a>（Dalpiciclib）联合<a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a>（pyrotinib）治疗<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a><a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, objectTitle=NAT COMMUN：达尔西利（Dalpiciclib）联合吡咯替尼（pyrotinib）治疗HER2阳性晚期乳腺癌的单臂II期临床试验, objectType=article, longId=795214, objectId=0cbce95214d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301008/1696780084045_6145188.jpg, objectUrl=/article/show_article.do?id=0cbce95214d8, replyNumber=0, likeNumber=103, createdTime=2023-10-13, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0cbce95214d8, moduleTitle=NAT COMMUN：达尔西利（Dalpiciclib）联合吡咯替尼（pyrotinib）治疗HER2阳性晚期乳腺癌的单臂II期临床试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0cbce95214d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2145871, encodeId=648921458e14a, content=<a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a>联合<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>治疗HR阳性、HER2 阳性转移性<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, objectTitle=BMC Medicine：吡咯替尼联合来曲唑治疗HR阳性、HER2 阳性转移性乳腺癌（PLEHERM）：一项多中心、单臂、II 期试验, objectType=article, longId=779380, objectId=1418e7938033, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230629/1688053459374_6145188.png, objectUrl=/article/show_article.do?id=1418e7938033, replyNumber=0, likeNumber=115, createdTime=2023-07-01, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1418e7938033, moduleTitle=BMC Medicine：吡咯替尼联合来曲唑治疗HR阳性、HER2 阳性转移性乳腺癌（PLEHERM）：一项多中心、单臂、II 期试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1418e7938033)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2130154, encodeId=a7992130154fb, content=中国医学科学院<a href='/topic/show?id=4804503e4d0' target=_blank style='color:#2F92EE;'>#徐兵河#</a>团队发现<a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a>加<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>可显著提高<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>的总生存期, objectTitle=STTT | 中国医学科学院徐兵河团队发现吡咯替尼加卡培他滨可显著提高HER2阳性转移性乳腺癌的总生存期, objectType=article, longId=763783, objectId=7163e63783ea, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/health-insurance-PK235DP.jpg, objectUrl=/article/show_article.do?id=7163e63783ea, replyNumber=0, likeNumber=125, createdTime=2023-05-05, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7163e63783ea, moduleTitle=STTT | 中国医学科学院徐兵河团队发现吡咯替尼加卡培他滨可显著提高HER2阳性转移性乳腺癌的总生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7163e63783ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1052515, encodeId=57de1052515f8, content=<a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a><a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, objectTitle=Front Oncol：吡咯替尼+长春瑞滨VS拉帕替尼+卡培他滨用于转移性HER-2阳性经治乳腺癌患者的疗效对比：多中心回顾性研究, objectType=article, longId=217280, objectId=228d21e2804b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021918/1631932054973_1611618.jpg, objectUrl=/article/show_article.do?id=228d21e2804b, replyNumber=0, likeNumber=141, createdTime=2021-09-18, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=228d21e2804b, moduleTitle=Front Oncol：吡咯替尼+长春瑞滨VS拉帕替尼+卡培他滨用于转移性HER-2阳性经治乳腺癌患者的疗效对比：多中心回顾性研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=228d21e2804b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

吡咯替尼

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #曲妥珠单抗# #白蛋白结合型紫杉醇# #吡咯替尼#

2024 ESMO BC | 吡咯替尼加曲妥珠单抗和白蛋白结合型紫杉醇三联疗法在HER2阳性乳腺癌新辅助治疗中的iDFS结果

2024-05-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #HER2# #多西他赛# #吡咯替尼#

Nat. Commun：吡咯替尼联合多西紫杉醇作为HER2阳性转移性乳腺癌的一线治疗：PANDORA II期临床试验

2024-01-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #吡咯替尼# #多西紫杉醇#

Nat. Commun | 吡罗替尼联合多西紫杉醇作为HER2阳性转移性乳腺癌的一线治疗：PANDORA II期试验

2024-01-15发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #吡咯替尼# #局部放疗#

客观缓解率近90%！JAMA子刊：乳腺癌脑转移治疗迎来突破！

2024-01-10发表于陕西省

侠胆医心 (审核中...)

前往app查看评论内容

#吡咯替尼#联合#卡瑞利珠单抗#和化疗一线治疗#HER2阳性#晚期#胃癌#具有令人惊喜的疗效结果。

疾病控制率100%！《柳叶刀》子刊：胃癌一线治疗有望迎来重磅疗法！

2023-11-30发表于威斯康星

侠胆医心 (审核中...)

前往app查看评论内容

#达尔西利#（Dalpiciclib）联合#吡咯替尼#（pyrotinib）治疗#HER2阳性晚期乳腺癌##乳腺癌#

NAT COMMUN：达尔西利（Dalpiciclib）联合吡咯替尼（pyrotinib）治疗HER2阳性晚期乳腺癌的单臂II期临床试验

2023-10-13发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

#吡咯替尼#联合#来曲唑#治疗HR阳性、HER2 阳性转移性#乳腺癌#

BMC Medicine：吡咯替尼联合来曲唑治疗HR阳性、HER2 阳性转移性乳腺癌（PLEHERM）：一项多中心、单臂、II 期试验

2023-07-01发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

中国医学科学院#徐兵河#团队发现#吡咯替尼#加#卡培他滨#可显著提高#HER2阳性转移性乳腺癌#的总生存期

STTT | 中国医学科学院徐兵河团队发现吡咯替尼加卡培他滨可显著提高HER2阳性转移性乳腺癌的总生存期

2023-05-05发表于上海

病毒猎手 (审核中...)

前往app查看评论内容

#吡咯替尼##乳腺癌#

Front Oncol：吡咯替尼+长春瑞滨VS拉帕替尼+卡培他滨用于转移性HER-2阳性经治乳腺癌患者的疗效对比：多中心回顾性研究

2021-09-18

科室
- - 订阅+
  - 更多科室
工具
服务